Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations. 

Dr Tim Mok: A Pharmacist's Perspective on Balancing Costs and Outcomes

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Videos

Tiago Biachi, MD, PhD, discusses the challenges of treating gastrointestinal (GI) cancers, particularly the limited effectiveness of immunotherapy for "cold tumors" and the need to make them more responsive to immune treatments.

Empowering Patients With GI Cancer: Overcoming Immunotherapy Limitations

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed. 

Efgartigimod Leads to Sustained Myasthenia Gravis Improvement

A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension (PAH). 

High Uric Acid Appears to Have Causal Role in PAH

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Exploring Novel Treatment Options for Alopecia Areata

Video Series

Epidemiology Associated With Alopecia Areata

Video content above is prompted by the following:

Ungar: What is the epidemiology of AA, and can you describe the different forms of AA that you see in your practice?

Is there a population in which AA occurs more frequently based on your clinical experience?


Panelists discuss how recent advancements, particularly the introduction of Janus kinase JAK inhibitors, are reshaping the treatment landscape for Aalopecia Aareata, offering new therapeutic options and addressing unmet needs in both efficacy and patient care.

Panelists discuss how alopecia areata (AA) is a chronic autoimmune disease characterized by inflammation that attacks hair follicles, leading to hair loss and varying disease progression.

Discussing the Pathophysiology of Alopecia Areata

Panelists discuss how the epidemiology of alopecia areata (AA) varies across different patient populations, with certain forms of the disease being more prevalent in specific groups.

Panelists discuss how concurrent comorbidities, such as thyroid disorders and other autoimmune conditions, are commonly seen in patients with alopecia areata (AA) and how they complicate disease management and increase the overall burden on patients.

Common Comorbidities Associated With Alopecia Areata

Panelists discuss how alopecia areata (AA) presents with hallmark symptoms such as sudden hair loss, and how the condition fluctuates over time, making it a relapsing or remitting inflammatory disease.

Hallmark Symptoms Seen With Alopecia Areata

Panelists discuss how ongoing or recurrent hair loss in patients with alopecia areata (AA) leads to significant psychological effects, impacting their mental health, and how different forms of AA may be harder for some patients to cope with, with strategies for managing these psychological challenges in clinical practice.

Psychosocial Impact of Alopecia Areata

Alopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss, primarily due to the immune system's attack on hair follicles. The pathophysiology involves a breakdown in immune privilege of hair follicles, leading to an inflammatory response. Cytotoxic T cells, particularly CD8+ T cells, infiltrate the hair follicle, causing hair loss. Inflammation plays a crucial role, with cytokines such as IFN-γ and TNF-α contributing to the immune-mediated destruction of hair follicles. The chronic nature of AA is attributed to persistent immune dysregulation and genetic predisposition.

Epidemiology Associated With Alopecia Areata

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Epidemiology Associated With Alopecia Areata

EP: 3.Common Comorbidities Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata